Blab Business
Max Healthcare Shares Surge 6% After Citi Keeps Buy Rating
Shares of Max Healthcare Institute Ltd. leapt 6.27% on Thursday, closing at ₹1,090.45 on the National Stock Exchange after Citi reiterated its buy recommendation and a ₹1,240 target price.
The rally was sparked by Citi’s assessment that the recent dip in the stock represents a buying opportunity and that the company’s long‑term growth prospects remain robust. The share price peaked at ₹1,095.60 during the session, up from the previous close of ₹1,026.15.
In its note, Citi described Max Healthcare as "preparing for a long haul" and projected an improvement in both its balance sheet and return on capital employed (RoCE) as the firm pursues an aggressive expansion plan. The brokerage added that near‑term challenges are likely to be transient and that disruptions in the oncology business should be largely absorbed in the first half of the fiscal year.
Citi also forecast a compound annual growth rate (CAGR) of roughly 20% for earnings before interest, tax, depreciation and amortisation (EBITDA) between FY26 and FY30. The bullish outlook attracted buying interest, propelling Max Healthcare to the top of the gainers list on the benchmark indices.
Headquartered in Delhi, Max Healthcare operates 22 hospitals and more than 5,000 beds across North India. The company also runs the Max Lab pathology and Max@Home home medical services divisions. Its expansion strategy has involved acquiring new hospital sites and developing specialty units, particularly in oncology.
The rating comes on the heels of the company’s report of a 10% year‑on‑year increase in gross revenue and a 4% rise in network operating EBITDA in Q3 FY26. Citi’s confidence in the firm’s balance‑sheet resilience and capital‑efficiency metrics aligns with the company’s recent financial performance.
Investors responded to the rating by buying shares, which pushed the stock to the top of the gainers list. The rally reflects broader market optimism around Indian healthcare providers that are expanding their service footprints while maintaining profitability.
The stock’s performance will be closely watched ahead of Max Healthcare’s next earnings announcement, expected in the second quarter of FY27. Market participants will look for confirmation of the projected EBITDA growth and the company’s ability to manage the oncology disruption mentioned by Citi.
In summary, Max Healthcare’s shares gained more than 6% after Citi maintained a buy rating and a ₹1,240 target price. The brokerage’s analysis points to long‑term growth potential, balance‑sheet improvement, and a 20% EBITDA CAGR forecast for FY26‑FY30. The stock’s surge has positioned it as a top gainer on the NSE, and investors will monitor the company’s upcoming earnings for further validation of Citi’s outlook.
The rally was sparked by Citi’s assessment that the recent dip in the stock represents a buying opportunity and that the company’s long‑term growth prospects remain robust. The share price peaked at ₹1,095.60 during the session, up from the previous close of ₹1,026.15.
In its note, Citi described Max Healthcare as "preparing for a long haul" and projected an improvement in both its balance sheet and return on capital employed (RoCE) as the firm pursues an aggressive expansion plan. The brokerage added that near‑term challenges are likely to be transient and that disruptions in the oncology business should be largely absorbed in the first half of the fiscal year.
Citi also forecast a compound annual growth rate (CAGR) of roughly 20% for earnings before interest, tax, depreciation and amortisation (EBITDA) between FY26 and FY30. The bullish outlook attracted buying interest, propelling Max Healthcare to the top of the gainers list on the benchmark indices.
Headquartered in Delhi, Max Healthcare operates 22 hospitals and more than 5,000 beds across North India. The company also runs the Max Lab pathology and Max@Home home medical services divisions. Its expansion strategy has involved acquiring new hospital sites and developing specialty units, particularly in oncology.
The rating comes on the heels of the company’s report of a 10% year‑on‑year increase in gross revenue and a 4% rise in network operating EBITDA in Q3 FY26. Citi’s confidence in the firm’s balance‑sheet resilience and capital‑efficiency metrics aligns with the company’s recent financial performance.
Investors responded to the rating by buying shares, which pushed the stock to the top of the gainers list. The rally reflects broader market optimism around Indian healthcare providers that are expanding their service footprints while maintaining profitability.
The stock’s performance will be closely watched ahead of Max Healthcare’s next earnings announcement, expected in the second quarter of FY27. Market participants will look for confirmation of the projected EBITDA growth and the company’s ability to manage the oncology disruption mentioned by Citi.
In summary, Max Healthcare’s shares gained more than 6% after Citi maintained a buy rating and a ₹1,240 target price. The brokerage’s analysis points to long‑term growth potential, balance‑sheet improvement, and a 20% EBITDA CAGR forecast for FY26‑FY30. The stock’s surge has positioned it as a top gainer on the NSE, and investors will monitor the company’s upcoming earnings for further validation of Citi’s outlook.
